In conclusion, since KRAS mutation is so common in PDAC, the detection of KRAS mutation in fluid or tumor tissue can have an important impact on the diagnosis, prognosis evaluation and treatment decision of PDAC. This evidence concerns the gene KRAS and neoplasm.